A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 653,660 shares of RARE stock, worth $30.3 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
653,660
Previous 539,749 21.1%
Holding current value
$30.3 Million
Previous $22.2 Million 63.68%
% of portfolio
0.1%
Previous 0.06%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.21 - $59.36 $4.58 Million - $6.76 Million
113,911 Added 21.1%
653,660 $36.3 Million
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $17.9 Million - $24.7 Million
478,849 Added 786.29%
539,749 $22.2 Million
Q1 2024

May 15, 2024

SELL
$43.02 - $53.69 $1.79 Million - $2.23 Million
-41,600 Reduced 40.59%
60,900 $2.84 Million
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $19.5 Million - $30.2 Million
-613,962 Reduced 85.69%
102,500 $4.9 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $10.2 Million - $13.6 Million
291,588 Added 68.63%
716,462 $25.5 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $35.9 Million - $50.2 Million
-961,987 Reduced 69.36%
424,874 $19.6 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $24.4 Million - $32.1 Million
659,174 Added 90.58%
1,386,861 $55.6 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $12.7 Million - $17.5 Million
377,000 Added 107.5%
727,687 $33.7 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $3.08 Million - $5.1 Million
77,172 Added 28.21%
350,687 $14.5 Million
Q2 2022

Aug 15, 2022

SELL
$45.8 - $85.4 $2.06 Million - $3.84 Million
-44,982 Reduced 14.12%
273,515 $16.3 Million
Q1 2022

May 16, 2022

SELL
$62.2 - $84.4 $6.68 Million - $9.06 Million
-107,377 Reduced 25.21%
318,497 $23.1 Million
Q4 2021

Feb 14, 2022

BUY
$73.71 - $87.86 $6.3 Million - $7.51 Million
85,500 Added 25.12%
425,874 $35.8 Million
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $28.6 Million - $37.6 Million
-366,926 Reduced 51.88%
340,374 $30.7 Million
Q2 2021

Aug 16, 2021

BUY
$92.19 - $115.71 $54.2 Million - $68 Million
587,700 Added 491.39%
707,300 $67.4 Million
Q1 2021

May 17, 2021

SELL
$106.9 - $167.73 $10,690 - $16,773
-100 Reduced 0.08%
119,600 $13.6 Million
Q4 2020

Feb 16, 2021

BUY
$84.4 - $177.39 $10.1 Million - $21.2 Million
119,700 New
119,700 $16.6 Million
Q1 2020

May 15, 2020

SELL
$33.8 - $62.9 $3.97 Million - $7.39 Million
-117,496 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$36.08 - $45.83 $2.23 Million - $2.83 Million
61,680 Added 110.51%
117,496 $5.02 Million
Q3 2019

Nov 15, 2019

BUY
$42.5 - $63.11 $916,002 - $1.36 Million
21,553 Added 62.9%
55,816 $2.39 Million
Q2 2019

Aug 14, 2019

BUY
$54.93 - $74.36 $1.88 Million - $2.55 Million
34,263 New
34,263 $2.18 Million
Q1 2019

May 15, 2019

SELL
$39.87 - $69.36 $6.93 Million - $12 Million
-173,700 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$38.89 - $77.3 $5.39 Million - $10.7 Million
138,700 Added 396.29%
173,700 $7.55 Million
Q3 2018

Nov 14, 2018

SELL
$71.81 - $90.15 $1.8 Million - $2.25 Million
-25,000 Reduced 41.67%
35,000 $2.67 Million
Q2 2018

Aug 14, 2018

SELL
$48.54 - $85.31 $485,400 - $853,100
-10,000 Reduced 14.29%
60,000 $4.61 Million
Q1 2018

May 15, 2018

SELL
$44.33 - $58.52 $1.04 Million - $1.37 Million
-23,400 Reduced 25.05%
70,000 $3.57 Million
Q4 2017

Feb 14, 2018

BUY
$43.54 - $57.32 $1.89 Million - $2.49 Million
43,400 Added 86.8%
93,400 $4.33 Million
Q3 2017

Nov 14, 2017

BUY
$49.79 - $66.32 $2.49 Million - $3.32 Million
50,000
50,000 $2.66 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.25B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.